Takeda Pharmaceutical Co is to expand its footprint in the US oncology market with the US$4.66 billion purchase of Ariad Pharmaceuticals Inc, adding one potential blockbuster in lung cancer and another already on-the-market therapy.
Takeda is to pay US$24 per share for Ariad, the companies said in a statement on Monday, 75 percent more than its Friday close of US$13.74. The deal would give it Ariad’s drug brigatinib, an experimental therapy being tested in lung cancer, and Iclusig, which is estimated to have brought in US$170.5 million last year.
The announcement came at the start of the JP Morgan Healthcare Conference in San Francisco, the year’s biggest gathering of healthcare investors and companies.
Takeda, based in Osaka, has been on a hunt for new drugs to replenish a flagging pipeline after patents have expired on some of its biggest products. As international drugmakers have spent billions on acquisitions in the last two years, Japanese drugmakers stayed largely on the sidelines.
However, they are now facing increased pressures at home, as the government attempts to lower the prices of many branded medicines and put a greater focus on generics to manage its healthcare spending.
In an interview, Takeda chief executive officer Christophe Weber said that “potentially” more deals could follow, although the company will remain disciplined.
Ariad has submitted brigatinib to regulators at the US Food and Drug Administration for review, with an expected decision by April 29. Meant to treat a form of non-small cell cancer, the therapy could have annual peak sales of more than US$1 billion, the company said.
The Cambridge, Massachusetts-based company’s drug Iclusig treats a rare advanced form of the blood cancer leukemia and has been the subject of controversy for its pricing of the pill. In October last year, US Senator Bernie Sanders decried the company’s “greed” in setting the list price of the drug at almost US$200,000 per year.
“Whether the premium of over 70 percent for the acquisition is justified depends on synergies ahead,” Morgan Stanley MUFG Securities Co analysts wrote in a research note about the Ariad acquisition, pointing to strong competition from other top drugs in the cancer space.
Takeda said in the statement that the deal is expected to add to its earnings by its fiscal year ending March 2019.
Takeda has been looking abroad as domestic growth slows and turned its focus on three therapeutic areas — gastroenterology, oncology and the central nervous system.
The Ariad deal is complementary to Takeda’s strategy on oncology, which is part of its core with gastroenterology and the central nervous system, Weber said in the interview, adding that there are no plans to expand into other therapy areas for now.
In January last year, Ariad elevated a new chief executive officer, Paris Panayiotopoulos, amid pressure from activist investor Alex Denner.
The drugmaker then slashed 19 percent of the company’s workforce and undertook what it called a “strategic review.”
“We will look at all situations but we are very responsible about all prices,” Weber said about drug pricing.
From the customer’s perspective, car rental is a straightforward business. The only uncertainty is whether the hire company will charge you for the scratch they discover when you hand back the vehicle. Hertz Global Holdings Inc’s bankruptcy protection filing on Friday last week was a reminder that today even the simplest business models are underpinned by a lot more financial complexity than meets the eye. The proximate cause of Hertz’s demise was of course the sudden collapse in bookings caused by COVID-19 travel restrictions. The company’s monthly revenue last month fell 73 percent year-on-year, a shortfall that even the most resilient
Uber Technologies Inc, Lyft Inc and Airbnb Inc have slashed thousands of jobs. Salesforce.com Inc and Visa Inc are letting employees work remotely for months; Twitter Inc and Square Inc are allowing them to do so for good. For the companies’ hometown of San Francisco, the moves are early signs of a dire blow. In a city with a long history of booms, busts and natural calamities, the COVID-19 pandemic has suddenly upended nearly a decade of prosperity. While municipalities across the US are grappling with economic fallout from the virus, San Francisco stands to take a deeper hit given its high
BULK PURCHASE: The French chain and Hong Kong-based Dairy Farm International reached a deal covering 224 stores, which is expected to be finalized by year’s end Carrefour SA yesterday announced it would acquire Wellcome Taiwan Co (惠康百貨) for 97 million euros (US$108.33 million), and bring all the Wellcome supermarkets (頂好超市) and Jasons Market Place stores nationwide under its banner within 12 months of the deal closing. The France-based hypermarket chain reached an agreement with Hong Kong-based Dairy Farm International Holdings (牛奶國際控股), the pan-Asian retailer that launched Wellcome Taiwan in 1987. The transaction involves 199 Wellcome supermarkets, which have average sales areas of 420m2 and 25 high-end Jasons Market Place stores, which have an average sales area of 820m2, as well as a warehouse in Taoyuan, Carrefour Taiwan (家樂福)
‘ONE-STOP SHOP’: A Miaoli official said that the factory in the Jhunan section of the Hsinchu Science Park would create more than 1,000 jobs and boost prosperity A new high-end IC packaging and testing plant planned by contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) in Miaoli County is expected to start operations in the middle of next year, Miaoli County Commissioner Hsu Yao-chang (徐耀昌) said. Hsu wrote on Facebook that TSMC, the world’s largest pure wafer foundry operator, would invest NT$303.2 billion (US$10.1 billion) to build the plant, the largest-ever single investment in Taiwan. However, TSMC declined to disclose the financial terms of the deal, while a company board meeting on May 12 approved a spending plan worth NT$168.2 billion as part of its investment plans. Construction of the